Sector
PharmaceuticalsOpen
₹1,842.1Prev. Close
₹1,857.05Turnover(Lac.)
₹29.26Day's High
₹1,870Day's Low
₹1,835.3552 Week's High
₹2,215.2452 Week's Low
₹1,047.62Book Value
₹0Face Value
₹10Mkt Cap (₹ Cr.)
1,875.92P/E
85.52EPS
21.73Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 9.61 | 9.61 | 9.61 | 9.61 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 106.4 | 86.64 | 67.85 | 53.8 |
Net Worth | 116.01 | 96.25 | 77.46 | 63.41 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 79.45 | 58.04 | 50.56 | |
yoy growth (%) | 14.79 | 21.4 | ||
Raw materials | -43.44 | -30.44 | -27.18 | |
As % of sales | 54.68 | 52.44 | 53.75 | |
Employee costs | -6.05 | -3.41 | -1.88 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 9.88 | 7.46 | 6.83 | |
Depreciation | -5.26 | -2.57 | -2.42 | -1.85 |
Tax paid | -2.9 | 0.24 | -0.07 | |
Working capital | 6.55 | 5.39 | -7.9 | 17.2 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.79 | 21.4 | ||
Op profit growth | 8.99 | 29.86 | ||
EBIT growth | 4.45 | 29.28 | ||
Net profit growth | 14.05 | 58.42 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 295.71 | 227.11 | 183.84 | 116.12 | 90.81 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 295.71 | 227.11 | 183.84 | 116.12 | 90.81 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 1.36 | 0.75 | 0.76 | 0.5 | 0.41 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,803.9 | 137.43 | 4,32,960 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,215.5 | 79.59 | 1,65,003.32 | 594 | 0.48 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,551.7 | 26.92 | 1,25,285.64 | 1,438.15 | 0.84 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,325.1 | 61.67 | 1,12,502.67 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,599.2 | 55.53 | 1,07,385.94 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Balwant Singh.
Joint Managing Director
Varun Batra
Chairperson & M D
Rahul Batra
Independent Director
Manmohan Khanna
Independent Director
Rohit Parti
Company Sec. & Compli. Officer
Rajni Brar
Whole-time Director
Ashutosh Shukla
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Beta Drugs Ltd
Summary
Beta Drugs Limited was incorporated as a private limited company with the name Beta Drugs Private limited at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to Beta Drugs Limited on August 11, 2017 Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014. The company is primarily engaged in the manufacturing of oncology products. The Companys products range from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new state of the art manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017. In October, 2017, the Company came up with a Public Issue of 22,96,000 Eq
Read More
The Beta Drugs Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1858.35 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Beta Drugs Ltd is ₹1875.92 Cr. as of 24 Apr ‘25
The PE and PB ratios of Beta Drugs Ltd is 85.52 and 16.17 as of 24 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Beta Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Beta Drugs Ltd is ₹1047.62 and ₹2215.24 as of 24 Apr ‘25
Beta Drugs Ltd's CAGR for 5 Years at 105.30%, 3 Years at 43.52%, 1 Year at 42.01%, 6 Month at 11.96%, 3 Month at 5.13% and 1 Month at -1.71%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.